MediWound Ltd. announced an agreement with Holy Stone Healthcare Co., Ltd. for the distribution of NexoBrid® in Taiwan for the treatment of severe burns. Commercialization of NexoBrid in Taiwan will commence after receipt of local regulatory approvals, which will be filed with the local regulatory authorities by Holy Stone Healthcare and is expected to be granted within two years or possibly longer. The agreement with Holy Stone Healthcare is similar to other global distribution agreements for NexoBrid that the Company currently has in Latin America, Asia Pacific, India and CIS regions, and is in line with MediWound's strategy to expand the availability of NexoBrid worldwide.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
17.65 TWD | +4.44% | +0.86% | -9.83% |
1st Jan change | Capi. | |
---|---|---|
-9.83% | 66.46M | |
+22.96% | 562B | |
-5.24% | 358B | |
+16.49% | 322B | |
+8.28% | 297B | |
+12.15% | 219B | |
+6.43% | 199B | |
-9.94% | 196B | |
-8.75% | 149B | |
-5.21% | 146B |
- Stock Market
- Equities
- 4194 Stock
- News Holy Stone Healthcare Co., Ltd.
- MediWound Ltd. Announces an Agreement with Holy Stone Healthcare, Co., Ltd. for the Distribution of NexoBrid® in Taiwan for the Treatment of Severe Burns